A Study to Investigate the Pharmacokinetic/Pharmacodynamic Characteristics of IBI128(A New Xanthine Oxidase Inhibitor)

NCT06277752 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

30

Enrollment

INDUSTRY

Sponsor class

Conditions

Gout Arthritis

Interventions

DRUG: dose-5 group
DRUG: dose-1 group
DRUG: dose-2 group
DRUG: dose-4 group
DRUG: dose-3 group

Sponsor

Innovent Biologics (Suzhou) Co. Ltd.